| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Center for the Study of Neurodegenerative Diseases and the Departments of Neurology (Drs. Swerdlow, Bennett, and Parker; J.K. Parks, D.S. Cassarino, and R.S. Maguire), Pediatrics (Dr. Parker), Pharmacology, and Behavioral Medicine (Dr. Bennett), University of Virginia Health Sciences Center, Charlottesville, VA; the Department of Science and Technology (Dr. Maguire), Griffith University, Brisbane, Australia; and MitoKor (Dr. Davis), San Diego, CA.
Address correspondence and reprint requests to Dr. Russell H. Swerdlow, Department of Neurology, Box 394, University of Virginia Health Sciences Center, Charlottesville, VA 22908.
The mitochondrial electron transport chain enzyme cytochrome c oxidase (COX) is defective in patients with sporadic Alzheimer's disease(AD). This defect arises from the mutation of mitochondrial DNA (mtDNA). To develop a tissue culture system that would express this genetically derived bioenergetic lesion and permit characterization of its functional consequences, we depleted Ntera2/D1 (NT2) teratocarcinoma cells of endogenous mtDNA and repopulated them with platelet mtDNA from AD patients. Cytochrome c oxidase activity was depressed in the resulting AD cytoplasmic hybrids (cybrids) compared with cybrids prepared with mtDNA from non-AD controls. Reactive oxygen species (ROS) production and free radical scavenging enzyme activities were significantly elevated in AD cybrids. A COX defect in NT2 AD cybrid lines indicates that AD patients possess mtDNA COX gene mutations that are sufficient for determining this biochemical lesion. Expression of unique functional characteristics (increased ROS production and free radical scavenging enzyme activities) relevant to neurodegeneration demonstrates the utility of these cells in defining AD pathophysiology at a cellular level. This in vitro tissue culture model of AD may prove useful in drug screening.
R.H.S. is supported by NIH postdoctoral training grant NS07199. J.P.B. is supported by grant NS34325.
Received February 7, 1997. Accepted in final form June 26, 1997.
This article has been cited by other articles:
|
|
 |
|
  J. Yao, R. W. Irwin, L. Zhao, J. Nilsen, R. T. Hamilton, and R. D. Brinton Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease PNAS, August 25, 2009; 106(34): 14670 - 14675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Mosconi, R. Mistur, R. Switalski, M. Brys, L. Glodzik, K. Rich, E. Pirraglia, W. Tsui, S. De Santi, and M. J. de Leon Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease Neurology, February 10, 2009; 72(6): 513 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Mosconi, M. Brys, R. Switalski, R. Mistur, L. Glodzik, E. Pirraglia, W. Tsui, S. De Santi, and M. J. de Leon From the Cover: Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism PNAS, November 27, 2007; 104(48): 19067 - 19072. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Khan, R. M. Smigrodzki, and R. H. Swerdlow Cell and animal models of mtDNA biology: progress and prospects Am J Physiol Cell Physiol, February 1, 2007; 292(2): C658 - C669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Danielson, V. Carelli, G. Tan, A. Martinuzzi, A. H. V. Schapira, M.-L. Savontaus, and G. A. Cortopassi Isolation of transcriptomal changes attributable to LHON mutations and the cybridization process Brain, May 1, 2005; 128(5): 1026 - 1037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Keil, A. Bonert, C. A. Marques, I. Scherping, J. Weyermann, J. B. Strosznajder, F. Muller-Spahn, C. Haass, C. Czech, L. Pradier, et al. Amyloid {beta}-induced Changes in Nitric Oxide Production and Mitochondrial Activity Lead to Apoptosis J. Biol. Chem., November 26, 2004; 279(48): 50310 - 50320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhu, M. A. Smith, G. Perry, and G. Aliev Mitochondrial failures in Alzheimer's disease American Journal of Alzheimer's Disease and Other Dementias, November 1, 2004; 19(6): 345 - 352. [Abstract] [PDF]
|
|
|
|
 |
|
 A M Gibson, J A Edwardson, D M Turnbull, I G McKeith, C M Morris, and P F Chinnery No evidence of an association between the T16189C mtDNA variant and late onset dementia J. Med. Genet., January 1, 2004; 41(1): e7 - 7. [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Lin, D. K. Simon, C. H. Ahn, L. M. Kim, and M. F. Beal High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain Hum. Mol. Genet., January 1, 2002; 11(2): 133 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Christen Oxidative stress and Alzheimer disease1 Am. J. Clinical Nutrition, February 1, 2000; 71(2): 621s - 629s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Munoz and H. Feldman Causes of Alzheimer's disease Can. Med. Assoc. J., January 1, 2000; 162(1): 65 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. F Chinnery, N. Howell, R. M Andrews, and D. M Turnbull Mitochondrial DNA analysis: polymorphisms and pathogenicity J. Med. Genet., July 1, 1999; 36(7): 505 - 510. [Abstract] [Full Text]
|
|
|
|
|
|
E. A. Schon, E. A. Shoubridge, and C. T. Moraes Cybrids in Alzheimer's disease: A cellular model of the disease? Neurology, July 1, 1998; 51(1): 326 - 326. [Full Text] [PDF]
|
|
|
|
|
|
R. H. Swerdlow and D. W. Parker Cybrids in Alzheimer's disease: A cellular model of the disease? Neurology, July 1, 1998; 51(1): 326 - 327. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
